Julphar
Growth Score40DXBi Rank138Heat Score100Gulf Pharmaceutical Industries P.S.C.
UAE-based pharmaceutical manufacturer and the country's only insulin producer
Media
Preview imagery published alongside each story, linking back to the original.
Overview
Growth Score
Steady
Heat Score
Trending up
Details
- Operating Status
- Active
- Company Type
- Public (ADX-listed)
- Headquarters
- Ras Al Khaimah, United Arab Emirates
- Founded
- 1980
- Company Size
- 1000+ employees
- Revenue
- $100M-$500M (H1 2026 revenue reported at AED 573.7 million / ~$156.2 million from continuing operations)
- Website
- julphar.net
Stock listing
Abu Dhabi Securities Exchange (ADX): JULPHAR
Products & Services
General Medicines
Off-patent (generic-equivalent) medicines manufactured to originator quality standards, spanning cardiovascular, pain management, wound care and other therapeutic areas.
Insulin / Diabetes Solutions (recombinant DNA insulin)
Julphar is noted as one of the world's leading insulin manufacturers and the only MENA-based producer of local recombinant DNA insulin (branded historically as Julphar Diabetes Solutions).
MEBO / MEBO Scar
Moist Exposure Burn Ointment product line for treating burn injuries and scarring, and an associated scar-treatment product.
Vaccines
Vaccine manufacturing as part of Julphar's healthcare product portfolio.
Consumer Healthcare / Julphar Life
Consumer health division covering vitamin supplements and over-the-counter health products.
People
Technology
Tech stack
Financials
Abu Dhabi Securities Exchange (ADX): JULPHAR
Stock
Funding rounds
Projects
Julphar Signs Lease Agreement with Modon Industrial City for Saudi Arabia Manufacturing Facility
Julphar formalized a lease agreement with Modon (3rd Industrial City) in Saudi Arabia to build an integrated pharmaceutical manufacturing facility, part of a planned investment of roughly SAR 300 million (about AED 293 million) over the coming years, intended partly as an export platform to international markets including the US.
$80M
Dec 22, 2025
Julphar and Global Investment House Form Planet Pharmacies Joint Venture
Julphar and Kuwait's Global Investment House announced the formation of Planet Pharmacies LLC, a pharmacy retail chain venture valued at approximately USD 245 million at formation, with Julphar contributing a distribution arm reported at around USD 150 million.
$245M
Aug 15, 2026
Julphar Collaborates with IBM and SAP to Accelerate Enterprise Transformation
Julphar announced a strategic collaboration with IBM Consulting and SAP to modernize core operations via a RISE with SAP S/4HANA implementation, using IBM Consulting Advantage (AI-powered delivery), affecting finance, supply chain, manufacturing and HR functions across Julphar's 10 UAE manufacturing facilities. Quoted: CEO Basel Ziyadeh, IBM Consulting Managing Partner Lula Mohanty, and SAP MEA South Senior VP Sergio Maccotta.
Jul 20, 2026
Gulf Pharmaceutical Industries (Julphar) Announces its Strategy 2030
Julphar announced its 'Strategy 2030' plan built on six pillars to drive sustainable growth, targeting over 100 new products.
Aug 14, 2026
Similar Companies
Official Channels
Where Julphar publishes directly. Each link is checked for the correct platform and profile format.
A tick means the link resolves to a valid company profile URL on that platform. It does not confirm the account is operated by Julphar — that requires a signal only the platform or the company can give, so DXBi does not claim it.
Press & Announcements
Every item links back to its original source. Announcements are only marked as coming from Julphar when the link resolves to the company's own domain.


